GSK Revolade, Xyzal get Japanese approval
Revolade is an oral treatment that stimulates the production of blood platelets, which are essential to normal clotting. GSK claimed that the anti-allergic drug, Xyzal, has been approved
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.